Pre-market Trend | KalVista Pharma (KALV) surged nearly 40% on 4/29, can the capital frenzy continue?

Yesterday's closing, KalVista Pharma's stock price soared 38.62%, closing at $26.67, with an intraday high of $26.76 and a trading volume reaching $1.904 billion, showing several times the average daily level. The MACD daily line formed a bullish signal above the zero axis, combined with such a fierce influx of funds, indicating a typical event-driven violent surge in the technical aspect. Such a huge trading volume means that large-scale funds are actively involved, and market sentiment is in an extremely euphoric state. From the news perspective, the activity level of funds in the biotechnology sector significantly increased yesterday, and KalVista, as a biopharmaceutical company focused on rare diseases such as hereditary angioedema, is likely to have surged due to major clinical progress or collaboration news. The biotechnology sector has frequently seen event-driven market trends recently, and the market is highly sensitive to breakthroughs in innovative drug pipelines. Against the macro backdrop of the Federal Reserve maintaining interest rates, high beta biotechnology stocks often become the focus of speculative funds. From a technical perspective, a nearly 40% increase in a single day indicates that short-term profit-taking has become very substantial, and the stock price has significantly deviated from the short-term moving average system, placing the technical aspect in a severely overbought area. Today, it is crucial to closely monitor whether there are sustained positive news to support the price; if there are no new catalysts, the probability of significant fluctuations or even a rapid pullback during the day is not low. The area around $19 (yesterday's opening range) can be seen as the first reference area for a pullback